IL91063A - 5,6,7,8-טטרהידרו - h4-תיאזולו ]b-4 ,5[ אזפנים, הכנתם ותכשירים המכילים אותם לעיכוב ליפואוקסיגנאזה ויצירת ליפופראוקסיד - Google Patents
5,6,7,8-טטרהידרו - h4-תיאזולו ]b-4 ,5[ אזפנים, הכנתם ותכשירים המכילים אותם לעיכוב ליפואוקסיגנאזה ויצירת ליפופראוקסידInfo
- Publication number
- IL91063A IL91063A IL9106389A IL9106389A IL91063A IL 91063 A IL91063 A IL 91063A IL 9106389 A IL9106389 A IL 9106389A IL 9106389 A IL9106389 A IL 9106389A IL 91063 A IL91063 A IL 91063A
- Authority
- IL
- Israel
- Prior art keywords
- group
- compound
- substituted
- amino
- thiazolo
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 24
- 102000003820 Lipoxygenases Human genes 0.000 title claims description 8
- 108090000128 Lipoxygenases Proteins 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000000203 mixture Substances 0.000 title description 72
- 150000001538 azepines Chemical class 0.000 title description 2
- 125000003118 aryl group Chemical group 0.000 claims abstract description 32
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 29
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 17
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 15
- 125000002252 acyl group Chemical group 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 270
- 238000000034 method Methods 0.000 claims description 145
- -1 nitro, amino Chemical group 0.000 claims description 138
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 70
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 15
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- PFGSHLUUDKSOKG-UHFFFAOYSA-N 2-[2-(2,3-dimethoxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound COC1=CC=CC(C=CC=2SC=3NCCCCC=3N=2)=C1OC PFGSHLUUDKSOKG-UHFFFAOYSA-N 0.000 claims 1
- SGZFKGOOQPVXCY-UHFFFAOYSA-N 2-[2-(2-methoxy-3-methylphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound COC1=C(C)C=CC=C1C=CC(S1)=NC2=C1NCCCC2 SGZFKGOOQPVXCY-UHFFFAOYSA-N 0.000 claims 1
- QDYZNDCOSOHBIK-UHFFFAOYSA-N 2-[2-(3,4,5-trimethoxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound COC1=C(OC)C(OC)=CC(C=CC=2SC=3NCCCCC=3N=2)=C1 QDYZNDCOSOHBIK-UHFFFAOYSA-N 0.000 claims 1
- ZEHJQOQWEYEYKN-UHFFFAOYSA-N 2-[2-(4-methoxy-3-methylphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=C(C)C(OC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 ZEHJQOQWEYEYKN-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- WRDQLFOQEXCULO-UHFFFAOYSA-N 2h-[1,3]thiazolo[5,4-b]azepine Chemical class C1=CC=CC2=NCSC2=N1 WRDQLFOQEXCULO-UHFFFAOYSA-N 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 159
- 238000000921 elemental analysis Methods 0.000 description 134
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 103
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 95
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 93
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 93
- 101150041968 CDC13 gene Proteins 0.000 description 91
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 49
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 41
- 230000003472 neutralizing effect Effects 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 238000005755 formation reaction Methods 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 29
- 239000002904 solvent Substances 0.000 description 29
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 16
- 229910002027 silica gel Inorganic materials 0.000 description 16
- 238000001816 cooling Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 12
- PJHKXESPJOFGOA-UHFFFAOYSA-N 1h-azepine;dihydrochloride Chemical compound Cl.Cl.N1C=CC=CC=C1 PJHKXESPJOFGOA-UHFFFAOYSA-N 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 229940086542 triethylamine Drugs 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- KUKJHGXXZWHSBG-GMPNNLDHSA-N 12-HHTrE Chemical compound CCCCCC(O)\C=C\C=C\C\C=C\CCCC(O)=O KUKJHGXXZWHSBG-GMPNNLDHSA-N 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- 230000010410 reperfusion Effects 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940073584 methylene chloride Drugs 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- AJUMGSLQADLWKL-UHFFFAOYSA-N 1h-azepine;hydrochloride Chemical compound Cl.N1C=CC=CC=C1 AJUMGSLQADLWKL-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 235000006408 oxalic acid Nutrition 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- BOWUOGIPSRVRSJ-UHFFFAOYSA-N 2-aminohexano-6-lactam Chemical compound NC1CCCCNC1=O BOWUOGIPSRVRSJ-UHFFFAOYSA-N 0.000 description 5
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 5
- 230000010933 acylation Effects 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 125000003282 alkyl amino group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000004623 platelet-rich plasma Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- MHJQKVZUHVVCRV-UHFFFAOYSA-N 2-phenyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C1=CC=CC=C1 MHJQKVZUHVVCRV-UHFFFAOYSA-N 0.000 description 4
- VTQGYRVGBASLDF-UHFFFAOYSA-N 4-aminoazepan-2-one Chemical compound NC1CCCNC(=O)C1 VTQGYRVGBASLDF-UHFFFAOYSA-N 0.000 description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 229960002089 ferrous chloride Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000008383 nephritis Diseases 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- HJVAVGOPTDJYOJ-UHFFFAOYSA-N 2-amino-4,5-dimethoxybenzoic acid Chemical compound COC1=CC(N)=C(C(O)=O)C=C1OC HJVAVGOPTDJYOJ-UHFFFAOYSA-N 0.000 description 2
- AXEVMSJERWWREB-UHFFFAOYSA-N 2-methyl-5-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)benzonitrile Chemical compound C1=C(C#N)C(C)=CC=C1C(S1)=NC2=C1NCCCC2 AXEVMSJERWWREB-UHFFFAOYSA-N 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N 3-Hydroxy 4-Methoxy Cinnamic acid Chemical compound COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- XKFIFYROMAAUDL-UHFFFAOYSA-N 3-amino-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1N XKFIFYROMAAUDL-UHFFFAOYSA-N 0.000 description 2
- NMJXONBGHJOWPZ-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(S1)=NC2=C1NCCCC2 NMJXONBGHJOWPZ-UHFFFAOYSA-N 0.000 description 2
- RDEYORKJEDLLDB-DQVHGTJVSA-N 5-Hydroperoxyeicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C(\OO)=C\C=C\C(O)=O RDEYORKJEDLLDB-DQVHGTJVSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- RAGYQTGMAGPCHM-UHFFFAOYSA-N CC(C)C1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound CC(C)C1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N RAGYQTGMAGPCHM-UHFFFAOYSA-N 0.000 description 2
- ATJYKSJXRNCNAX-UHFFFAOYSA-N COC1=CC(=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)OC Chemical compound COC1=CC(=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)OC ATJYKSJXRNCNAX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000005236 alkanoylamino group Chemical group 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000006627 ethoxycarbonylamino group Chemical group 0.000 description 2
- AMDAYXCXAYTGKD-UHFFFAOYSA-N ethyl [4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)phenyl] carbonate Chemical compound C1=CC(OC(=O)OCC)=CC=C1C(S1)=NC2=C1NCCCC2 AMDAYXCXAYTGKD-UHFFFAOYSA-N 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000006626 methoxycarbonylamino group Chemical group 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- WTBAHSZERDXKKZ-UHFFFAOYSA-N octadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCCCC(Cl)=O WTBAHSZERDXKKZ-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000003396 thiol group Chemical class [H]S* 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- USBXWYPSFPIJDR-UHFFFAOYSA-N (2-methyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepin-4-yl)-pyridin-3-ylmethanone Chemical compound C1=2SC(C)=NC=2CCCCN1C(=O)C1=CC=CN=C1 USBXWYPSFPIJDR-UHFFFAOYSA-N 0.000 description 1
- QVHJQCGUWFKTSE-YFKPBYRVSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)OC(C)(C)C QVHJQCGUWFKTSE-YFKPBYRVSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 description 1
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 1
- UWTJARDNAKLKCS-ZXVVBBHZSA-N (e)-1-(4-tert-butylphenyl)-n-[4-(naphthalen-1-ylmethyl)piperazin-1-yl]methanimine Chemical compound C1=CC(C(C)(C)C)=CC=C1\C=N\N1CCN(CC=2C3=CC=CC=C3C=CC=2)CC1 UWTJARDNAKLKCS-ZXVVBBHZSA-N 0.000 description 1
- RRLUFPHCTSFKNR-DUXPYHPUSA-N (e)-3-(3,4-dichlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C(Cl)=C1 RRLUFPHCTSFKNR-DUXPYHPUSA-N 0.000 description 1
- ZCJLOOJRNPHKAV-ONEGZZNKSA-N (e)-3-(furan-2-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CO1 ZCJLOOJRNPHKAV-ONEGZZNKSA-N 0.000 description 1
- CQNPVMCASGWEHM-VMPITWQZSA-N (e)-3-[4-(dimethylamino)phenyl]prop-2-enoic acid Chemical compound CN(C)C1=CC=C(\C=C\C(O)=O)C=C1 CQNPVMCASGWEHM-VMPITWQZSA-N 0.000 description 1
- WOGITNXCNOTRLK-VOTSOKGWSA-N (e)-3-phenylprop-2-enoyl chloride Chemical compound ClC(=O)\C=C\C1=CC=CC=C1 WOGITNXCNOTRLK-VOTSOKGWSA-N 0.000 description 1
- AVNQDTIVRGNOGA-WLHGVMLRSA-N (e)-but-2-enedioic acid;3-(4-methylpiperazin-1-yl)-1-(2-phenyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepin-4-yl)propan-1-one Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCN1CCC(=O)N1C(SC(=N2)C=3C=CC=CC=3)=C2CCCC1 AVNQDTIVRGNOGA-WLHGVMLRSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FEGVSPGUHMGGBO-SREVYHEPSA-N (z)-3-(2-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=CC=C1\C=C/C(O)=O FEGVSPGUHMGGBO-SREVYHEPSA-N 0.000 description 1
- YEOZQWRDUXNFTF-UHFFFAOYSA-N 1,2-dimethylbenzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N(C)C(C)=NC2=C1 YEOZQWRDUXNFTF-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- FLUXJRKGXWUSCL-UHFFFAOYSA-N 1-bromopentane 2-[2-(4-methoxy-3-pentoxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepine Chemical compound C(CCCC)Br.COC1=C(C=C(C=CC=2SC=3NCCCCC3N2)C=C1)OCCCCC FLUXJRKGXWUSCL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KUKJHGXXZWHSBG-WBGSEQOASA-N 12S-HHTrE Chemical compound CCCCC[C@H](O)\C=C\C=C\C\C=C/CCCC(O)=O KUKJHGXXZWHSBG-WBGSEQOASA-N 0.000 description 1
- BIAIZATYCMOMBP-UHFFFAOYSA-N 1h-azepine;oxalic acid Chemical compound OC(=O)C(O)=O.N1C=CC=CC=C1 BIAIZATYCMOMBP-UHFFFAOYSA-N 0.000 description 1
- RIZUCYSQUWMQLX-UHFFFAOYSA-N 2,3-dimethylbenzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1C RIZUCYSQUWMQLX-UHFFFAOYSA-N 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-N 2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- ONOTYLMNTZNAQZ-UHFFFAOYSA-N 2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC=C1F ONOTYLMNTZNAQZ-UHFFFAOYSA-N 0.000 description 1
- MGDJNZUQCAWWOX-UHFFFAOYSA-N 2,6-ditert-butyl-4-(5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepin-2-yl)phenol Chemical compound CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2SC=3NCCCCC=3N=2)=C1 MGDJNZUQCAWWOX-UHFFFAOYSA-N 0.000 description 1
- AKJGCHUITIAULN-UHFFFAOYSA-N 2,6-ditert-butyl-4-(5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepin-2-yl)phenol hydrochloride Chemical compound Cl.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=2SC=3NCCCCC=3N=2)=C1 AKJGCHUITIAULN-UHFFFAOYSA-N 0.000 description 1
- KKIXGLUMZGQOSX-UHFFFAOYSA-N 2,6-ditert-butyl-4-[2-(5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepin-2-yl)ethenyl]phenol oxalic acid Chemical compound OC(=O)C(O)=O.CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(C=CC=2SC=3NCCCCC=3N=2)=C1 KKIXGLUMZGQOSX-UHFFFAOYSA-N 0.000 description 1
- FNUWDRVVDQTRJW-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;hydrochloride Chemical compound Cl.C1CCCNC(S2)=C1N=C2C1=CC=C2OCOC2=C1 FNUWDRVVDQTRJW-UHFFFAOYSA-N 0.000 description 1
- QBOGUFMLIHOCCC-UHFFFAOYSA-N 2-(1-methylpyrrol-2-yl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;hydrochloride Chemical compound Cl.CN1C=CC=C1C(S1)=NC2=C1NCCCC2 QBOGUFMLIHOCCC-UHFFFAOYSA-N 0.000 description 1
- SLLKONTZQXTCJR-UHFFFAOYSA-N 2-(1-phenylpropyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound N=1C=2CCCCNC=2SC=1C(CC)C1=CC=CC=C1 SLLKONTZQXTCJR-UHFFFAOYSA-N 0.000 description 1
- TWFSQCLIQASWKS-UHFFFAOYSA-N 2-(1H-indol-2-yl)-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepine Chemical compound N1CCCCC2=C1SC(C=1NC3=CC=CC=C3C=1)=N2 TWFSQCLIQASWKS-UHFFFAOYSA-N 0.000 description 1
- XCRVFSBZAZVGRI-UHFFFAOYSA-N 2-(1H-pyrrol-2-yl)-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-b]azepine dihydrochloride Chemical compound Cl.Cl.S1C=2NCCCCC=2N=C1C1=CC=CN1 XCRVFSBZAZVGRI-UHFFFAOYSA-N 0.000 description 1
- ZLOIAWYKSFBPSY-UHFFFAOYSA-N 2-(2,6-difluorophenyl)-4-ethyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2N(CC)CCCCC=2N=C1C1=C(F)C=CC=C1F ZLOIAWYKSFBPSY-UHFFFAOYSA-N 0.000 description 1
- FYUQLYDYEPWQAO-UHFFFAOYSA-N 2-(2,6-difluorophenyl)-4-methyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepine;hydrochloride Chemical compound Cl.S1C=2N(C)CCCCC=2N=C1C1=C(F)C=CC=C1F FYUQLYDYEPWQAO-UHFFFAOYSA-N 0.000 description 1
- WUZXJLZBJILJFK-UHFFFAOYSA-N 2-(2-phenylethenyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C=CC1=CC=CC=C1 WUZXJLZBJILJFK-UHFFFAOYSA-N 0.000 description 1
- MHQQMQDQDNHCBO-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C(S1)=NC2=C1NCCCC2 MHQQMQDQDNHCBO-UHFFFAOYSA-N 0.000 description 1
- HMEUTLQAWRCYBM-UHFFFAOYSA-N 2-(3-nitrophenyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound [O-][N+](=O)C1=CC=CC(C=2SC=3NCCCCC=3N=2)=C1 HMEUTLQAWRCYBM-UHFFFAOYSA-N 0.000 description 1
- NGUBSBWOGWOOFU-UHFFFAOYSA-N 2-(3h-benzimidazol-5-yl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;dihydrochloride Chemical compound Cl.Cl.N1CCCCC2=C1SC(C=1C=C3NC=NC3=CC=1)=N2 NGUBSBWOGWOOFU-UHFFFAOYSA-N 0.000 description 1
- ZQLHMKCXFAAADK-UHFFFAOYSA-N 2-(4-methoxyphenyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1C(S1)=NC2=C1NCCCC2 ZQLHMKCXFAAADK-UHFFFAOYSA-N 0.000 description 1
- DACBICUQFYZQEW-UHFFFAOYSA-N 2-(4-phenylbuta-1,3-dienyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C=CC=CC1=CC=CC=C1 DACBICUQFYZQEW-UHFFFAOYSA-N 0.000 description 1
- NQSZOXKUYASBJK-UHFFFAOYSA-N 2-(4-phenylphenyl)-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C(C=C1)=CC=C1C1=CC=CC=C1 NQSZOXKUYASBJK-UHFFFAOYSA-N 0.000 description 1
- PGCSZPCDIDIMAM-UHFFFAOYSA-N 2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)ethanamine;dihydrochloride Chemical compound Cl.Cl.C1CCCNC2=C1N=C(CCN)S2 PGCSZPCDIDIMAM-UHFFFAOYSA-N 0.000 description 1
- WNAJXPYVTFYEST-UHFFFAOYSA-N 2-Amino-3-methylbenzoate Chemical compound CC1=CC=CC(C(O)=O)=C1N WNAJXPYVTFYEST-UHFFFAOYSA-N 0.000 description 1
- BXKKANHRUUQUGA-UHFFFAOYSA-N 2-[2-(1h-imidazol-5-yl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;dihydrochloride Chemical compound Cl.Cl.S1C=2NCCCCC=2N=C1C=CC1=CNC=N1 BXKKANHRUUQUGA-UHFFFAOYSA-N 0.000 description 1
- YJHHFTDGVPTDRX-UHFFFAOYSA-N 2-[2-(3,4-dimethylphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=C(C)C(C)=CC=C1C=CC(S1)=NC2=C1NCCCC2 YJHHFTDGVPTDRX-UHFFFAOYSA-N 0.000 description 1
- AKJNTSBAMAYDJY-UHFFFAOYSA-N 2-[2-(3-bromo-4-methoxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=C(Br)C(OC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 AKJNTSBAMAYDJY-UHFFFAOYSA-N 0.000 description 1
- XZBZPCBDCPTAFZ-UHFFFAOYSA-N 2-[2-(4-chlorophenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(Cl)=CC=C1C=CC(S1)=NC2=C1NCCCC2 XZBZPCBDCPTAFZ-UHFFFAOYSA-N 0.000 description 1
- CDCBAUIQIJMACS-UHFFFAOYSA-N 2-[2-(4-ethoxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(OCC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 CDCBAUIQIJMACS-UHFFFAOYSA-N 0.000 description 1
- RGLWDXBEHPLBAW-UHFFFAOYSA-N 2-[2-(4-methoxyphenyl)ethyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(OC)=CC=C1CCC(S1)=NC2=C1NCCCC2 RGLWDXBEHPLBAW-UHFFFAOYSA-N 0.000 description 1
- KKDXUYRDKLNILF-UHFFFAOYSA-N 2-[2-(4-methylphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(C)=CC=C1C=CC(S1)=NC2=C1NCCCC2 KKDXUYRDKLNILF-UHFFFAOYSA-N 0.000 description 1
- HCQXGHBMAKAQLU-UHFFFAOYSA-N 2-[2-(4-methylsulfanylphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(SC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 HCQXGHBMAKAQLU-UHFFFAOYSA-N 0.000 description 1
- BSUHYGRGHKTVFZ-UHFFFAOYSA-N 2-[2-(4-nitrophenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC([N+](=O)[O-])=CC=C1C=CC(S1)=NC2=C1NCCCC2 BSUHYGRGHKTVFZ-UHFFFAOYSA-N 0.000 description 1
- FRRZHDOZHCHMTQ-UHFFFAOYSA-N 2-[2-(4-propan-2-yloxyphenyl)ethenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(OC(C)C)=CC=C1C=CC(S1)=NC2=C1NCCCC2 FRRZHDOZHCHMTQ-UHFFFAOYSA-N 0.000 description 1
- WCQWRJUNMKQFFD-UHFFFAOYSA-N 2-[4-(4-methoxyphenyl)buta-1,3-dienyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1=CC(OC)=CC=C1C=CC=CC(S1)=NC2=C1NCCCC2 WCQWRJUNMKQFFD-UHFFFAOYSA-N 0.000 description 1
- BSUYALGPOUJFQF-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)phenyl]-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;trihydrochloride Chemical compound Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(C=2SC=3NCCCCC=3N=2)C=C1 BSUYALGPOUJFQF-UHFFFAOYSA-N 0.000 description 1
- NBUUUJWWOARGNW-UHFFFAOYSA-N 2-amino-5-methylbenzoic acid Chemical compound CC1=CC=C(N)C(C(O)=O)=C1 NBUUUJWWOARGNW-UHFFFAOYSA-N 0.000 description 1
- XHYVBIXKORFHFM-UHFFFAOYSA-N 2-amino-6-methylbenzoic acid Chemical compound CC1=CC=CC(N)=C1C(O)=O XHYVBIXKORFHFM-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000005999 2-bromoethyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- IAWLSXPHXWCMKF-UHFFFAOYSA-N 2-ethyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;oxalic acid Chemical compound OC(=O)C(O)=O.C1CCCNC2=C1N=C(CC)S2 IAWLSXPHXWCMKF-UHFFFAOYSA-N 0.000 description 1
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GAKYBDMOVARQHQ-UHFFFAOYSA-N 2-heptadecyl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound C1CCCNC2=C1N=C(CCCCCCCCCCCCCCCCC)S2 GAKYBDMOVARQHQ-UHFFFAOYSA-N 0.000 description 1
- DGZZNERJQNIZEA-UHFFFAOYSA-N 2-methoxy-5-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline;dihydrochloride Chemical compound Cl.Cl.C1=C(N)C(OC)=CC=C1C(S1)=NC2=C1NCCCC2 DGZZNERJQNIZEA-UHFFFAOYSA-N 0.000 description 1
- HHBXZWNZVQVKFC-UHFFFAOYSA-N 2-methyl-4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)benzonitrile Chemical compound C1=C(C#N)C(C)=CC(C=2SC=3NCCCCC=3N=2)=C1 HHBXZWNZVQVKFC-UHFFFAOYSA-N 0.000 description 1
- XGCBLLYAKVWQKH-UHFFFAOYSA-N 2-methyl-4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)benzonitrile;hydrochloride Chemical compound Cl.C1=C(C#N)C(C)=CC(C=2SC=3NCCCCC=3N=2)=C1 XGCBLLYAKVWQKH-UHFFFAOYSA-N 0.000 description 1
- ASUCRKAWRQDUCJ-UHFFFAOYSA-N 2-methyl-5-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline Chemical compound C1=C(N)C(C)=CC=C1C(S1)=NC2=C1NCCCC2 ASUCRKAWRQDUCJ-UHFFFAOYSA-N 0.000 description 1
- LYZMRUDZQIHMMW-UHFFFAOYSA-N 2-methyl-5-[2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)ethenyl]aniline;dihydrochloride Chemical compound Cl.Cl.C1=C(N)C(C)=CC=C1C=CC(S1)=NC2=C1NCCCC2 LYZMRUDZQIHMMW-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- IETWMJIOMYDOGH-UHFFFAOYSA-N 2-methyl-6-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC(C=2SC=3NCCCCC=3N=2)=C1N IETWMJIOMYDOGH-UHFFFAOYSA-N 0.000 description 1
- COPSJQVPEUUOKY-UHFFFAOYSA-N 2-methylsulfanylpyridine-3-carboxylic acid Chemical compound CSC1=NC=CC=C1C(O)=O COPSJQVPEUUOKY-UHFFFAOYSA-N 0.000 description 1
- HAYFGCJAFPKCBM-UHFFFAOYSA-N 2-morpholin-4-yl-1-(2-phenyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepin-4-yl)ethanone;hydrochloride Chemical compound Cl.C1CCCC=2N=C(C=3C=CC=CC=3)SC=2N1C(=O)CN1CCOCC1 HAYFGCJAFPKCBM-UHFFFAOYSA-N 0.000 description 1
- XMRLDTQVUWYEPQ-UHFFFAOYSA-N 2-naphthalen-2-yl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound N1CCCCC2=C1SC(C=1C=C3C=CC=CC3=CC=1)=N2 XMRLDTQVUWYEPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- CCTVQVLKCHZLMJ-UHFFFAOYSA-N 2-pyridin-2-yl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;dihydrochloride Chemical compound Cl.Cl.S1C=2NCCCCC=2N=C1C1=CC=CC=N1 CCTVQVLKCHZLMJ-UHFFFAOYSA-N 0.000 description 1
- QVUJUSRWGOXFGU-UHFFFAOYSA-N 2-pyridin-3-yl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine;dihydrochloride Chemical compound Cl.Cl.S1C=2NCCCCC=2N=C1C1=CC=CN=C1 QVUJUSRWGOXFGU-UHFFFAOYSA-N 0.000 description 1
- JPMKFKPAQMCJRX-UHFFFAOYSA-N 2-pyridin-4-yl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C1=CC=NC=C1 JPMKFKPAQMCJRX-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- NBTPFUNHZCDYIK-UHFFFAOYSA-N 2-thiophen-2-yl-5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepine Chemical compound S1C=2NCCCCC=2N=C1C1=CC=CS1 NBTPFUNHZCDYIK-UHFFFAOYSA-N 0.000 description 1
- RZIKQNPZPMTQCT-UHFFFAOYSA-N 3,4-dimethoxy-n-(2-oxoazepan-4-yl)benzamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1CC(=O)NCCC1 RZIKQNPZPMTQCT-UHFFFAOYSA-N 0.000 description 1
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 1
- SCJHPUGWYHCYAZ-UHFFFAOYSA-N 3,5-diethyl-2-propylpyridine Chemical compound CCCC1=NC=C(CC)C=C1CC SCJHPUGWYHCYAZ-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- MMRBOOWGZUHMBU-UHFFFAOYSA-N 3-(4-methylphenyl)prop-2-enethioic s-acid Chemical compound CC1=CC=C(C=CC(S)=O)C=C1 MMRBOOWGZUHMBU-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BLGNHBRAQBHMAB-UHFFFAOYSA-N 3-[3-methoxy-4-(methylsulfanylmethoxy)phenyl]prop-2-enoic acid Chemical compound COC1=CC(C=CC(O)=O)=CC=C1OCSC BLGNHBRAQBHMAB-UHFFFAOYSA-N 0.000 description 1
- DOERLUCWEUSMIF-UHFFFAOYSA-N 3-[4-(diethylazaniumyl)phenyl]prop-2-enoate Chemical compound CCN(CC)C1=CC=C(C=CC(O)=O)C=C1 DOERLUCWEUSMIF-UHFFFAOYSA-N 0.000 description 1
- FDGAEAYZQQCBRN-UHFFFAOYSA-N 3-amino-4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1N FDGAEAYZQQCBRN-UHFFFAOYSA-N 0.000 description 1
- GWSXYSZAGOCSNP-UHFFFAOYSA-N 3-cyano-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1C#N GWSXYSZAGOCSNP-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- GYCGGZVMDKSTEI-UHFFFAOYSA-N 3-methyl-2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline;dihydrochloride Chemical compound Cl.Cl.CC1=CC=CC(N)=C1C(S1)=NC2=C1NCCCC2 GYCGGZVMDKSTEI-UHFFFAOYSA-N 0.000 description 1
- BGJZHOJELYTQLC-UHFFFAOYSA-N 3-morpholin-4-yl-1-(2-phenyl-5,6,7,8-tetrahydro-[1,3]thiazolo[5,4-b]azepin-4-yl)propan-1-one;hydrochloride Chemical compound Cl.C1CCCC=2N=C(C=3C=CC=CC=3)SC=2N1C(=O)CCN1CCOCC1 BGJZHOJELYTQLC-UHFFFAOYSA-N 0.000 description 1
- NXTNASSYJUXJDV-UHFFFAOYSA-N 3-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(C(Cl)=O)=C1 NXTNASSYJUXJDV-UHFFFAOYSA-N 0.000 description 1
- PFUNSVRUCZAWKL-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)benzenecarboximidamide;dihydrochloride Chemical compound Cl.Cl.C1=CC(C(=N)N)=CC=C1C(S1)=NC2=C1NCCCC2 PFUNSVRUCZAWKL-UHFFFAOYSA-N 0.000 description 1
- YDIYEOMDOWUDTJ-UHFFFAOYSA-N 4-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-N 0.000 description 1
- NHFKECPTBZZFBC-UHFFFAOYSA-N 4-amino-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1N NHFKECPTBZZFBC-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 125000002391 4-chlorocinnamoyl group Chemical group 0.000 description 1
- LTRYUAZFLOGRLJ-UHFFFAOYSA-N 4-cyano-3-methylbenzoic acid Chemical compound CC1=CC(C(O)=O)=CC=C1C#N LTRYUAZFLOGRLJ-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- HAGJTIBXUDKELF-UHFFFAOYSA-N 4-methyl-2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline Chemical compound CC1=CC=C(N)C(C=2SC=3NCCCCC=3N=2)=C1 HAGJTIBXUDKELF-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- DVXULFCMKUIQTP-UHFFFAOYSA-N 5-chloro-2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline Chemical compound NC1=CC(Cl)=CC=C1C(S1)=NC2=C1NCCCC2 DVXULFCMKUIQTP-UHFFFAOYSA-N 0.000 description 1
- MMHCQUXTQOKLIQ-UHFFFAOYSA-N 5-hydroxyicosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC(O)=CC=CC(O)=O MMHCQUXTQOKLIQ-UHFFFAOYSA-N 0.000 description 1
- ZKAQPVQEYCFRTK-UHFFFAOYSA-N 5-methyl-1,2-oxazole-4-carbonyl chloride Chemical compound CC=1ON=CC=1C(Cl)=O ZKAQPVQEYCFRTK-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- LTUUGSGSUZRPRV-UHFFFAOYSA-N 6-methylpyridine-2-carboxylic acid Chemical compound CC1=CC=CC(C(O)=O)=N1 LTUUGSGSUZRPRV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- DFXQXFGFOLXAPO-UHFFFAOYSA-N 96-99-1 Chemical compound OC(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 DFXQXFGFOLXAPO-UHFFFAOYSA-N 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- LFGRBWHZDJHBMR-UHFFFAOYSA-N C1=CC(OC)=CC=C1C(=O)C1C(N)C(=O)NCCC1 Chemical compound C1=CC(OC)=CC=C1C(=O)C1C(N)C(=O)NCCC1 LFGRBWHZDJHBMR-UHFFFAOYSA-N 0.000 description 1
- GSQRULKQEBNOIL-UHFFFAOYSA-N C1CC(C(C(=O)NC1)N)C(=O)C2=CC=CC(=C2)C#N Chemical compound C1CC(C(C(=O)NC1)N)C(=O)C2=CC=CC(=C2)C#N GSQRULKQEBNOIL-UHFFFAOYSA-N 0.000 description 1
- UMDXJAYOHDGUFG-UHFFFAOYSA-N C1CCNC(=O)C(N)C1C(=O)C(C=1C=CC=CC=1)=CC1=CC=CC=C1 Chemical compound C1CCNC(=O)C(N)C1C(=O)C(C=1C=CC=CC=1)=CC1=CC=CC=C1 UMDXJAYOHDGUFG-UHFFFAOYSA-N 0.000 description 1
- BYDFGNGUGYUXKB-UHFFFAOYSA-N CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=CC(=O)C2CCCNC(=O)C2N Chemical compound CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=CC(=O)C2CCCNC(=O)C2N BYDFGNGUGYUXKB-UHFFFAOYSA-N 0.000 description 1
- NTNJHSWABQWJFI-UHFFFAOYSA-N CC(C)OC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound CC(C)OC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N NTNJHSWABQWJFI-UHFFFAOYSA-N 0.000 description 1
- GGSWTWAYERMXQD-UHFFFAOYSA-N CC1=C(C=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N)OC Chemical compound CC1=C(C=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N)OC GGSWTWAYERMXQD-UHFFFAOYSA-N 0.000 description 1
- PZEHDWSPPLFUBP-UHFFFAOYSA-N CC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound CC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N PZEHDWSPPLFUBP-UHFFFAOYSA-N 0.000 description 1
- FLXFPTWTLOOUMD-UHFFFAOYSA-N CCC(C1=CC=CC=C1)C(=O)C2CCCNC(=O)C2N Chemical compound CCC(C1=CC=CC=C1)C(=O)C2CCCNC(=O)C2N FLXFPTWTLOOUMD-UHFFFAOYSA-N 0.000 description 1
- RUSVHJRRLQYLIO-UHFFFAOYSA-N CCOC(=O)OC1=C(C=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N)OC Chemical compound CCOC(=O)OC1=C(C=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N)OC RUSVHJRRLQYLIO-UHFFFAOYSA-N 0.000 description 1
- NXDZRNQAAAEIAK-UHFFFAOYSA-N CCOC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound CCOC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N NXDZRNQAAAEIAK-UHFFFAOYSA-N 0.000 description 1
- KZWHGKYLNZHQIB-UHFFFAOYSA-N CN1CCN(CC1)C2=CC=C(C=C2)C(=O)C3CCCNC(=O)C3N Chemical compound CN1CCN(CC1)C2=CC=C(C=C2)C(=O)C3CCCNC(=O)C3N KZWHGKYLNZHQIB-UHFFFAOYSA-N 0.000 description 1
- UPQAYZFZQHYLQG-UHFFFAOYSA-N COC1=C(C(=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)OC)OC Chemical compound COC1=C(C(=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)OC)OC UPQAYZFZQHYLQG-UHFFFAOYSA-N 0.000 description 1
- MCMSUCUXUKMDHZ-UHFFFAOYSA-N COC1=C(C=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)Br Chemical compound COC1=C(C=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N)Br MCMSUCUXUKMDHZ-UHFFFAOYSA-N 0.000 description 1
- ZQZLNTXREFYECF-UHFFFAOYSA-N COC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound COC1=CC=C(C=C1)C=CC(=O)C2CCCNC(=O)C2N ZQZLNTXREFYECF-UHFFFAOYSA-N 0.000 description 1
- UNPWDONVNSSLRW-UHFFFAOYSA-N COC1=CC=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N Chemical compound COC1=CC=CC(=C1)C=CC(=O)C2CCCNC(=O)C2N UNPWDONVNSSLRW-UHFFFAOYSA-N 0.000 description 1
- JAXSHHQGAOHVCN-UHFFFAOYSA-N COC1=CC=CC=C1C=CC(=O)C1C(N)C(=O)NCCC1 Chemical compound COC1=CC=CC=C1C=CC(=O)C1C(N)C(=O)NCCC1 JAXSHHQGAOHVCN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- OJYGBLRPYBAHRT-OPKHMCHVSA-N Chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H](C(O)CO)OC21 OJYGBLRPYBAHRT-OPKHMCHVSA-N 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZVIDMSBTYRSMAR-UHFFFAOYSA-N N-Methyl-4-aminobenzoate Chemical compound CNC1=CC=C(C(O)=O)C=C1 ZVIDMSBTYRSMAR-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OKKZZUJEGFKZJG-UHFFFAOYSA-N NC(C(CCCN1)C(C(C=CC=C2)=C2F)=O)C1=O Chemical compound NC(C(CCCN1)C(C(C=CC=C2)=C2F)=O)C1=O OKKZZUJEGFKZJG-UHFFFAOYSA-N 0.000 description 1
- QGVQFSMFCRMQJZ-UHFFFAOYSA-N NC(C(CCCN1)C(C=CC(C=C2)=CC=C2Cl)=O)C1=O Chemical compound NC(C(CCCN1)C(C=CC(C=C2)=CC=C2Cl)=O)C1=O QGVQFSMFCRMQJZ-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000020339 Spinal injury Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- IPVLWFPRONTXLQ-UHFFFAOYSA-N [2-methyl-4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)phenyl]methanamine;dihydrochloride Chemical compound Cl.Cl.C1=C(CN)C(C)=CC(C=2SC=3NCCCCC=3N=2)=C1 IPVLWFPRONTXLQ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 210000001229 azygos vein Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- CJXILUAPNODSOZ-UHFFFAOYSA-N ethyl 4-[2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)ethenyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 CJXILUAPNODSOZ-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- ZXUQEPZWVQIOJE-UHFFFAOYSA-N methyl 2-chloro-2-oxoacetate Chemical compound COC(=O)C(Cl)=O ZXUQEPZWVQIOJE-UHFFFAOYSA-N 0.000 description 1
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- PKUOZBBYICEDGL-UHFFFAOYSA-N n,n-diethyl-4-[2-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)ethenyl]aniline Chemical compound C1=CC(N(CC)CC)=CC=C1C=CC(S1)=NC2=C1NCCCC2 PKUOZBBYICEDGL-UHFFFAOYSA-N 0.000 description 1
- WFGHQKYXGHELTJ-UHFFFAOYSA-N n,n-dimethyl-3-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline Chemical compound CN(C)C1=CC=CC(C=2SC=3NCCCCC=3N=2)=C1 WFGHQKYXGHELTJ-UHFFFAOYSA-N 0.000 description 1
- DUSFEAPYCPQHFG-UHFFFAOYSA-N n,n-dimethyl-4-(5,6,7,8-tetrahydro-4h-[1,3]thiazolo[5,4-b]azepin-2-yl)aniline Chemical compound C1=CC(N(C)C)=CC=C1C(S1)=NC2=C1NCCCC2 DUSFEAPYCPQHFG-UHFFFAOYSA-N 0.000 description 1
- YRHBFDYJRYOCJQ-UHFFFAOYSA-N n-(2-oxoazepan-3-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1CCCCNC1=O YRHBFDYJRYOCJQ-UHFFFAOYSA-N 0.000 description 1
- GAPVQDIWTUPZIX-UHFFFAOYSA-N n-(2-oxoazepan-4-yl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC1CCCNC(=O)C1 GAPVQDIWTUPZIX-UHFFFAOYSA-N 0.000 description 1
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005029 naphthylthio group Chemical group C1(=CC=CC2=CC=CC=C12)S* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N p-toluenesulfonic acid Substances CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005440 p-toluyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000002071 phenylalkoxy group Chemical group 0.000 description 1
- 125000004660 phenylalkylthio group Chemical group 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RIBFXMJCUYXJDZ-UHFFFAOYSA-N propanoyl bromide Chemical compound CCC(Br)=O RIBFXMJCUYXJDZ-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 208000022064 reactive hyperemia Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008268 response to external stimulus Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18422088 | 1988-07-22 | ||
| JP8653689 | 1989-04-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL91063A0 IL91063A0 (en) | 1990-02-09 |
| IL91063A true IL91063A (he) | 1994-12-29 |
Family
ID=26427638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9106389A IL91063A (he) | 1988-07-22 | 1989-07-21 | 5,6,7,8-טטרהידרו - h4-תיאזולו ]b-4 ,5[ אזפנים, הכנתם ותכשירים המכילים אותם לעיכוב ליפואוקסיגנאזה ויצירת ליפופראוקסיד |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US4956360A (he) |
| EP (1) | EP0351856B1 (he) |
| JP (1) | JP3054738B2 (he) |
| KR (1) | KR970011396B1 (he) |
| AT (1) | ATE184610T1 (he) |
| AU (1) | AU610739B2 (he) |
| CA (1) | CA1336431C (he) |
| DE (1) | DE68929074T2 (he) |
| DK (1) | DK362889A (he) |
| IL (1) | IL91063A (he) |
| NZ (1) | NZ230042A (he) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89351A0 (en) * | 1988-03-14 | 1989-09-10 | Lundbeck & Co As H | 4,5,6,7-tetrahydroisothiazolo(4,5-c)pyridines,process for their preparation and pharmaceutical compositions containing them |
| DE3820775A1 (de) * | 1988-06-20 | 1989-12-21 | Thomae Gmbh Dr K | Neue 4,5,7,8-tetrahydro-6h-thiazolo(5,4,-d)azepine, ihre herstellung und ihre verwendung als arzneimittel |
| DE4134467A1 (de) * | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| IL97249A (he) * | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | תרכובות של 7,6,5,4-טטרהידרותיאזולו ]b-5,4[פירידין ותרכובות של 5,6-דיהידרו- h4-פירולו ]d-3,2[ תיאזולו, ייצורן, והרכבים רוקחיים הכוללים או |
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9219779D0 (en) * | 1992-09-18 | 1992-10-28 | Rhone Poulenc Agriculture | Compositions of new matter |
| DE4324580A1 (de) * | 1993-07-22 | 1995-01-26 | Thomae Gmbh Dr K | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| AU5857296A (en) * | 1995-05-17 | 1996-11-29 | Eli Lilly And Company | Use of leukotriene antagonists for alzheimer's disease |
| US5891460A (en) * | 1995-06-07 | 1999-04-06 | University Of Southern California University Park Campus | Method for reducing or preventing post-surgical adhesion formation using ketotifen and analogs thereof |
| GB2312621B (en) * | 1996-05-02 | 1998-03-11 | Pharma Nord Uk Limited | Anti-oxidant medicament |
| US6433935B2 (en) | 1996-07-02 | 2002-08-13 | Three-Five Systems, Inc. | Display illumination system |
| AU5886500A (en) * | 1999-06-23 | 2001-01-09 | Sepracor, Inc. | Indolyl-benzimidazole antibacterials, and methods of use thereof |
| US6649318B1 (en) | 2000-04-20 | 2003-11-18 | Eastman Kodak Company | Self-contained imaging media comprising microencapsulated color formers and a resilient layer |
| RU2188824C1 (ru) * | 2000-12-18 | 2002-09-10 | Военно-медицинская академия | 2-амино-4-ацетилтиазоло[5,4-b]индол, защищающий организм от воздействия гипоксии и токсического отека легкого |
| EP1424101A3 (en) * | 2002-11-29 | 2004-08-18 | NOZAKI, Masako | Use of a leukotriene C4 and D4 receptor antagonist for the preparation of a medicament for treating or preventing brain inflammation and sepsis |
| US7148248B2 (en) | 2002-11-29 | 2006-12-12 | Masako Nozaki | Method of treating or inhibiting the development of brain inflammation and sepsis |
| KR101228268B1 (ko) * | 2003-12-01 | 2013-01-31 | 캠브리지 엔터프라이즈 리미티드 | 항-염증제 |
| RU2281950C2 (ru) * | 2004-09-21 | 2006-08-20 | Военно-медицинская академия им. С.М. Кирова | 4-АЦЕТИЛТИАЗОЛО[5,4-b]ИНДОЛ-2-СУКЦИНИМИД, ЗАЩИЩАЮЩИЙ ОРГАНИЗМ ОТ ГИПОКСИИ И ОБЛАДАЮЩИЙ ПРОФИЛАКТИЧЕСКИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ ТОКСИЧЕСКОГО ОТЕКА ЛЕГКОГО |
| WO2006134384A1 (en) | 2005-06-15 | 2006-12-21 | Cambridge Enterprise Limited | Anti-inflammatory agents |
| GB201009603D0 (en) * | 2010-06-08 | 2010-07-21 | Cambridge Entpr Ltd | Anti-inflammatory agent |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG17968A3 (bg) * | 1970-08-14 | 1974-03-05 | Dr. Karl Thomae Gmbh | Метод за получаване на производни на азепина |
| JPS53121781A (en) * | 1977-03-30 | 1978-10-24 | Torii Yakuhin Kk | Caprolactum derivatives |
| AU554388B2 (en) * | 1981-06-15 | 1986-08-21 | American Home Products Corporation | Alpha-phenyl-2-(aza)benzothiazolylthioglycolic acid derivatives |
| JPS5837097A (ja) * | 1981-08-28 | 1983-03-04 | 味の素株式会社 | 界面活性剤 |
| JPS63283591A (ja) * | 1986-12-17 | 1988-11-21 | Toray Ind Inc | L−α−アミノ−ε−カプロラクタムの製造法 |
-
1989
- 1989-07-19 JP JP01187790A patent/JP3054738B2/ja not_active Expired - Lifetime
- 1989-07-20 DE DE68929074T patent/DE68929074T2/de not_active Expired - Fee Related
- 1989-07-20 EP EP89113362A patent/EP0351856B1/en not_active Expired - Lifetime
- 1989-07-20 AT AT89113362T patent/ATE184610T1/de not_active IP Right Cessation
- 1989-07-21 US US07/383,071 patent/US4956360A/en not_active Expired - Lifetime
- 1989-07-21 AU AU38862/89A patent/AU610739B2/en not_active Ceased
- 1989-07-21 IL IL9106389A patent/IL91063A/he not_active IP Right Cessation
- 1989-07-21 DK DK362889A patent/DK362889A/da not_active Application Discontinuation
- 1989-07-21 CA CA000606328A patent/CA1336431C/en not_active Expired - Fee Related
- 1989-07-21 NZ NZ230042A patent/NZ230042A/en unknown
- 1989-07-22 KR KR1019890010423A patent/KR970011396B1/ko not_active Expired - Lifetime
-
1990
- 1990-07-27 US US07/558,507 patent/US5118806A/en not_active Expired - Fee Related
-
1992
- 1992-03-17 US US07/852,657 patent/US5300639A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA1336431C (en) | 1995-07-25 |
| US5300639A (en) | 1994-04-05 |
| KR910002873A (ko) | 1991-02-26 |
| EP0351856A2 (en) | 1990-01-24 |
| JPH0347188A (ja) | 1991-02-28 |
| US5118806A (en) | 1992-06-02 |
| EP0351856A3 (en) | 1991-08-07 |
| DK362889A (da) | 1990-01-23 |
| DE68929074D1 (de) | 1999-10-21 |
| AU3886289A (en) | 1990-01-25 |
| AU610739B2 (en) | 1991-05-23 |
| KR970011396B1 (ko) | 1997-07-10 |
| US4956360A (en) | 1990-09-11 |
| NZ230042A (en) | 1990-10-26 |
| DK362889D0 (da) | 1989-07-21 |
| EP0351856B1 (en) | 1999-09-15 |
| JP3054738B2 (ja) | 2000-06-19 |
| DE68929074T2 (de) | 2000-01-05 |
| ATE184610T1 (de) | 1999-10-15 |
| IL91063A0 (en) | 1990-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1336431C (en) | Thiazolo(5,4-b)azepine compounds | |
| AU2003265585B2 (en) | Calcium receptor modulating compound and use thereof | |
| DE69221988T2 (de) | Verfahren zur Herstellung substituierter Maleimide | |
| KR100394761B1 (ko) | 헤테로바이사이클릭유도체 | |
| JP5092402B2 (ja) | ピラゾロピリジン誘導体 | |
| EP3548468B1 (en) | Tricyclic rho kinase inhibitors | |
| CA2763960C (en) | Bicyclic and tricyclic compounds as kat ii inhibitors | |
| WO2008027466A1 (en) | Hydantoin derivatives useful as antibacterial agents | |
| EP2590942A1 (en) | Rho kinase inhibitors | |
| SK126993A3 (en) | Thiopyranopyrrole derivatives, method of their preparation and pharmaceutical compositions containing them | |
| EP0579496A1 (en) | 4-Aminoquinazoline derivatives, and their use as medicine | |
| CA2036905C (en) | Condensed thiazole compounds, their production and use | |
| WO2016100166A1 (en) | SUBSTITUTED DIHYDRO-1H-PYRROLO[3,2-c]PYRIDIN-4(5H)-ONES AS RIPK3 INHIBITORS | |
| WO2011048525A1 (en) | Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators | |
| JPH03206042A (ja) | 降圧剤 | |
| US6977262B2 (en) | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | |
| JP3111321B2 (ja) | 縮合チアゾール化合物 | |
| US4703051A (en) | 4,7-dihydrothieno[2,3-B]pyridine derivatives useful in the treatment of cardiovascular diseases | |
| US6506773B2 (en) | Hydroxamic and carboxylic acid derivatives | |
| JP3358069B2 (ja) | 三環性複素環類、その製造法及び剤 | |
| Youssef | Reactions of 2-amino-4, 5, 6, 7-tetrahydro [1] benzothiophene-3-carbonitrile and 6-amino-1, 4-dihydro-3-methyl-1, 4-diphenylpyrano [2, 3-c] pyrazole-5-carbonitrile with substituted benzylidenemalononitriles, α, β-acetylenic esters and ketones | |
| CN115141204A (zh) | 一种萘[1,2-b]呋喃-4,5-二酮衍生物其制备及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |